Table 3.
Overview of the Representative Studies Reporting HPV Prevalence in HPV-Related Cancers
| Author | Tumor type | Tested participants (N) | Age | HPV subtype | HPV positive (%) | Most common HPV subtype (%)* | Detection method |
|---|---|---|---|---|---|---|---|
| Komloš et al. 2011 | Anal (invasive and in situ) | 21 | NA | High-risk and low-risk HPV; 6, 16, 52, 61 | 95.8 | HPV-16 (90.5) | GP5+/6+ PCR / Inno-LiPA |
|
| |||||||
| Tachezy et al. 2007 | Anal squamous cell carcinoma | 22 | Mean = 64.2; Range 47-86 | High-risk HPV 16 | 81.8 | HPV-16 (81.8) | GP5+/6+ PCR / RLB and sequencing |
|
| |||||||
| De Vuyst et al. 2009 | Anal (29 studies) | 955 | NA | HPV-18 HPV-33 |
84.3 | HPV-16 (73.4) | PCR |
|
| |||||||
| Vaginal (14 studies) | 136 | NA | HPV-18 HPV-31 |
69.9 | HPV-16 (53.7) | ||
|
| |||||||
| Vulvar (63 studies) | 1,873 | NA | HPV-33 HPV-18 HPV-6 HPV-11 |
40.4 | HPV-16 (32.3) | ||
|
| |||||||
| Frisch et al. 1997 | Anal (invasive and in situ) | 388 | Median = 63; Range 26-94 | High-risk HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 Low-risk HPV, 6, 11, 40, 42, 43, 44 |
84 | HPV-16 (73.4) | PCR |
|
| |||||||
| Škamperle et al. 2013 | Anal (3 studies) | 43 | NA | HPV-16, HPV- 6, HPV-52, HPV-61 | Overall HPV DNA prevalence = 90.7 | HPV-16 (94.9) | PCR (MY09/11 / DBH and sequencing GP5+/6+ PCR / RLB and sequencing HPV-16/18 TS PCR and Linear Array® MY09/11 / HPV-16 TS PCR and sequencing HPV-16/18 TS PCR MY09/11 PCR / RFLP MY09/11 PCR / pU-1M/2R PCR GP5+/6+ PCR / IA and RLB Inno-LiPA® MY09/11 PCR / HPV-16/18 TS PCR HPV-16, -18, -33 TS PCR E6-E7 consensus PCR / HPV-16, -18, -31, -33, -45, -52, -59, -68 TS PCR) |
|
| |||||||
| Cervical (24 studies) | 2,531 | Mean 50.2 | HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-35, HPV-39, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68 | Overall HPV DNA prevalence= 86.6 | (59.6) | ||
|
| |||||||
| Vulvar (3 studies) | 164 | NA | HPV-16, HPV-33, HPV-45, HPV-58, HPV-6, HPV-42 | Overall HPV DNA prevalence= 32.9 | (22) | ||
|
| |||||||
| Šimić et al. 2023 | Oral cavity, oropharynx | 76 | Median= 61 | High-risk HPV 16, 18 | 23.7 | HPV-16 (77.7) | PCR |
*
Prevalence. Inno-LiPA®=INNO-LiPA HPV Genotyping Extra test (Innogenetics NV, Ghent, Belgium) or INNO-LiPA HPV genotyping test (Labo Biomedical Products, Rijswijk, the Netherlands); Linear Array®=Linear Array® HPV genotyping test (Roche Molecular Systems Inc., Alameda, CA, USA); PCR=Polymerase chain reaction; TS PCR=Type-specific PCR; DBH=Dot-blot hybridization, RLB=Reverse line-blot hybridization; IA=Immuno-assay–enzyme-linked oligosorbent assay; NA=Not applicable; HPV=Human papillomavirus; DNA=Deoxyribonucleotide acid.